Maternal and perinatal outcomes of SARS‐CoV‐2 infection in unvaccinated pregnancies during Delta and Omicron waves

Ultrasound in Obstetrics and Gynecology, Journal Year: 2022, Volume and Issue: 60(1), P. 96 - 102

Published: April 20, 2022

There is little evidence related to the effects of Omicron severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant on pregnancy outcomes, particularly in unvaccinated women. This study aimed compare outcomes women infected with SARS-CoV-2 during pre-Delta, Delta and waves.

Language: Английский

---

COVID-19 vaccination in pregnancy

American Journal of Obstetrics and Gynecology, Journal Year: 2022, Volume and Issue: 227(2), P. 136 - 147

Published: May 11, 2022

Language: Английский

---

Preeclampsia up to date—What’s going on?

Hypertension Research, Journal Year: 2023, Volume and Issue: 46(8), P. 1900 - 1907

Published: June 2, 2023

Language: Английский

---

Deep learning in public health: Comparative predictive models for COVID-19 case forecasting

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(3), P. e0294289 - e0294289

Published: March 14, 2024

The COVID-19 pandemic has had a significant impact on both the United Arab Emirates (UAE) and Malaysia, emphasizing importance of developing accurate reliable forecasting mechanisms to guide public health responses policies. In this study, we compared several cutting-edge deep learning models, including Long Short-Term Memory (LSTM), bidirectional LSTM, Convolutional Neural Networks (CNN), hybrid CNN-LSTM, Multilayer Perceptron’s, Recurrent (RNN), project cases in aforementioned regions. These models were calibrated evaluated using comprehensive dataset that includes confirmed case counts, demographic data, relevant socioeconomic factors. To enhance performance these Bayesian optimization techniques employed. Subsequently, re-evaluated compare their effectiveness. Analytic approaches, predictive retrospective nature, used interpret data. Our primary objective was determine most effective model for predicting Malaysia. findings indicate selected algorithms proficient cases, although efficacy varied across different models. After thorough evaluation, architectures suitable specific conditions UAE Malaysia identified. study contributes significantly ongoing efforts combat pandemic, providing crucial insights into application sophisticated precise timely cases. hold substantial value shaping strategies, enabling authorities develop targeted evidence-based interventions manage virus spread its populations confirms usefulness methodologies efficiently processing complex datasets generating projections, skill great healthcare professional settings.

Language: Английский

---

Clinical severity of SARS‐CoV‐2 infection among vaccinated and unvaccinated pregnancies during the Omicron wave

Ultrasound in Obstetrics and Gynecology, Journal Year: 2022, Volume and Issue: 59(4), P. 560 - 562

Published: March 1, 2022

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly contagious and has significant alterations to its spike protein structure, providing it with ability evade immune response elicited by disease 2019 (COVID-19) vaccines1. This caused a record number new cases worldwide supplanted the Delta as dominant strain in most countries, including UK Turkey2. Recent reports suggest that Omicron-related COVID-19 milder compared Delta-related overall mortality rate for vaccinated individuals may be close seasonal flu3. However, these are based on data derived mostly from countries high vaccination rate, there no outcome infection unvaccinated pregnant women. Gray literature articles have contained coverage reduced effectiveness existing vaccines against better prognosis cases4. These factors affect negatively rates women whose uptake already relatively low5, 6. Therefore, evidence-based counseling, important document effect severity specific this variant. To end, we conducted retrospective cohort study real-time reverse transcriptase polymerase chain reaction (RT-PCR)-positive SARS-CoV-2 during pregnancy. Three tertiary care facilities participated (Sancaktepe Training Research Hospital, Istanbul, Turkey, Koc University St George's London, UK), identified between 27 December 2021 1 February 2022 were included. By mid-December 2021, more than half related both which gained complete dominance over second January 20227, 8. Inclusion criteria PCR-confirmed specified period pregnancy at time diagnosis. Fully (two doses), booster (more two doses) included, but those who partially (single dose) excluded analysis. Women received World Health Organization Emergency Use List (Comirnaty, messenger RNA (mRNA) CoronaVac, inactivated) within 6 months before diagnosis eligible inclusion. RT-PCR testing was performed symptoms, had contact infected or part screening admission unrelated reasons. Baseline characteristics (e.g. maternal age, body mass index, smoking status, gestational age diagnosis, vaccine doses comorbidities) recorded. Maternal index treated potential confounders9. main measures need oxygen supplementation. Disease categorized according National Institutes classification10. In brief, mild symptoms without lower tract involvement (no dyspnea abnormal lung imaging). Moderate hypoxemia (oxygen saturation room air ≥ 94%). Severe showed signs hypoxemia, evidenced (< 94%) imaging showing infiltrates > 50%. Cases any classified asymptomatic. Levels support via nasal cannula non-rebreather mask, non-invasive mechanical ventilation continuous positive airway pressure (CPAP), intubation extracorporeal membrane oxygenation. using chi-square test Mann–Whitney U-test, appropriate. All analyses R Statistical Computing Software P-values < 0.05 considered statistically significant. During inclusion period, 135 infection, whom 83 52 not. Among vaccinated, 70 (84.3%) 13 (15.7%) three doses. women, 78 (94.0%) mRNA minority inactivated (n = 2) combination 3). No differences observed (median, 31.0 vs years, P 0.730), 26.7 27.3 kg/m2, 0.284), obesity (16.9% 21.2%, 0.606) trimester (P 0.254) (Table 1). Few medical comorbidities, asthma (7.2%), pregestational diabetes (2.4%), hypothyroidism malignancy (1.2%) immunosuppression (1.2%). There non-significant trend fewer comorbidities either asymptomatic pregnancies; contrast, five (9.6%) presented moderate SARS-CoV-2. significantly group (0.0 9.6%, 0.015). Two managed support, CPAP one required intubation. intensive unit 3.8% 0% group. deaths wave illness less likely require supplementation their counterparts. Our findings emphasize importance full protect despite apparently variant11. limited sample size, selection bias conditioned rather viral genotyping. It possible distribution variants differed evasion capabilities impossible ascribe single our relate (starting after when accounted majority cases) Data available request authors

Language: Английский

---

Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS‐CoV‐2 infection: analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico

Ultrasound in Obstetrics and Gynecology, Journal Year: 2021, Volume and Issue: 59(1), P. 76 - 82

Published: Oct. 21, 2021

Mortality in pregnancy due to coronavirus disease 2019 (COVID-19) is a current health priority developing countries. Identification of clinical and sociodemographic risk factors related mortality pregnant women with COVID-19 could guide public policy encourage such accept vaccination. We aimed evaluate the association comorbidities socioeconomic determinants COVID-19-related severe Mexico.This an ongoing nationwide prospective cohort study that includes all positive reverse-transcription quantitative polymerase chain reaction result for acute respiratory syndrome 2 (SARS-CoV-2) from Mexican National Registry Coronavirus. The primary outcome was maternal death COVID-19. characteristics explored using log-binomial regression model adjusted possible confounders.There were 176 (1.35%) deaths among 13 062 consecutive SARS-CoV-2-positive women. Maternal age, as continuous (adjusted relative (aRR), 1.08 (95% CI, 1.05-1.10)) or categorical variable, associated COVID-19; aged 35-39 years (aRR, 3.16 2.34-4.26)) 40 older 4.07 2.65-6.25)) had higher mortality, compared those < 35 years. Other pre-existing diabetes 2.66 1.65-4.27)), chronic hypertension 1.75 1.02-3.00)) obesity 2.15 1.46-3.17)). Very high social vulnerability 1.88 1.26-2.80)) 1.49 1.04-2.13)) increased while very low reduced 0.47 0.30-0.73)). Being poor extremely also 1.53 1.09-2.15) aRR, 1.83 1.32-2.53), respectively).This study, which comprises largest date, has confirmed advanced diabetes, hypertension, obesity, status are mortality. © 2021 International Society Ultrasound Obstetrics Gynecology.

Language: Английский

---

High-Dose Inhaled Nitric Oxide for the Treatment of Spontaneously Breathing Pregnant Patients With Severe Coronavirus Disease 2019 (COVID-19) Pneumonia

Obstetrics and Gynecology, Journal Year: 2022, Volume and Issue: unknown

Published: July 7, 2022

OBJECTIVE: To evaluate whether the use of inhaled nitric oxide (iNO) 200 improves respiratory function. METHODS: This retrospective cohort study used data from pregnant patients hospitalized with severe bilateral coronavirus disease 2019 (COVID-19) pneumonia at four teaching hospitals between March 2020 and December 2021. Two cohorts were identified: 1) those receiving standard care alone (SoC cohort) 2) iNO for 30 minutes twice daily in addition to (iNO cohort). Inhaled oxide, as a novel therapy, was offered only one hospital. The prespecified primary outcome days free any oxygen supplementation 28 postadmission. Secondary outcomes hospital length stay, rate intubation, intensive unit (ICU) stay. multivariable-adjusted regression analyses accounted age, body mass index, gestational steroids, remdesivir, center. RESULTS: Seventy-one COVID-19 pneumonia: 51 SoC 20 cohort. Patients had more supplementation–free : median [interquartile range], 24 [23–26] vs alone: 22 [14–24] days, P =.01) compared In analyses, associated 63.2% (95% CI 36.2–95.4%; <.001) supplementation, 59.7% 56.0–63.2%; shorter ICU 63.6% 55.1–70.8%; No -related adverse events reported. CONCLUSION: pneumonia, reduced need

Language: Английский

---

Pregnancy Outcomes, Immunophenotyping and Immunohistochemical Findings in a Cohort of Pregnant Patients with COVID-19—A Prospective Study

Diagnostics, Journal Year: 2023, Volume and Issue: 13(7), P. 1345 - 1345

Published: April 4, 2023

(1) Background: SARS-CoV-2 infection during pregnancy could determine important maternal and fetal complications. We aimed to prospectively assess placental immunohistochemical changes, immunophenotyping alterations, outcomes in a cohort of patients with COVID-19; (2) Methods: 52 pregnant admitted tertiary maternity center between October 2020 November 2021 were segregated into two equal groups, depending on the presence infection. Blood samples, fragments umbilical cord, amniotic membranes, along clinical data collected. Descriptive statistics conditional logistic regression model used for analysis; (3) Results: Adverse such as preterm labor neonatal intensive care unit admission did not significantly differ groups. The analysis indicated that moderate-severe forms COVID-19 had reduced population T lymphocytes, CD4+ cells, CD8+ cells (only numeric), CD4+/CD8+ index, B natural killer (NK) cells. Our immunohistochemistry tissue samples failed demonstrate positivity CD19, CD3, CD4, CD8, CD56 markers; (4) Conclusions: Immunophenotyping be useful risk stratification patients, while further studies are needed extent immunological decidual response various COVID-19.

Language: Английский

---

COVID-19 related maternal mortality cases in associated with Delta and Omicron waves and the role of lung ultrasound

Journal of Turkish Society of Obstetric and Gynecology, Journal Year: 2022, Volume and Issue: 19(2), P. 88 - 97

Published: June 27, 2022

To present coronavirus disease-2019 (COVID-19) related maternal mortality in relation to Delta and Omicron waves investigate the role of lung ultrasound (LUS) estimating mortality.

Language: Английский

---

COVID-19 booster doses in pregnancy and global vaccine equity

The Lancet, Journal Year: 2022, Volume and Issue: 399(10328), P. 907 - 908

Published: Feb. 18, 2022

Language: Английский

---